Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
- PMID: 39137731
- PMCID: PMC11428204
- DOI: 10.1016/j.ccell.2024.07.009
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Figures
Erratum for
-
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.Cancer Cell. 2017 Apr 10;31(4):532-548.e7. doi: 10.1016/j.ccell.2017.02.017. Epub 2017 Mar 23. Cancer Cell. 2017. PMID: 28344039 Free PMC article.
Similar articles
-
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.Cancer Cell. 2017 Jun 12;31(6):844-847. doi: 10.1016/j.ccell.2017.05.001. Cancer Cell. 2017. PMID: 28609659 No abstract available.
-
Role of the TMPRSS2-ERG gene fusion in prostate cancer.Neoplasia. 2008 Feb;10(2):177-88. doi: 10.1593/neo.07822. Neoplasia. 2008. PMID: 18283340 Free PMC article.
-
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.Br J Cancer. 2007 Dec 17;97(12):1690-5. doi: 10.1038/sj.bjc.6604054. Epub 2007 Oct 30. Br J Cancer. 2007. PMID: 17971772 Free PMC article.
-
Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis.Cancer Cell Int. 2018 Nov 12;18:177. doi: 10.1186/s12935-018-0672-2. eCollection 2018. Cancer Cell Int. 2018. PMID: 30459527 Free PMC article. Review.
-
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.Cancer Cell Int. 2014 Apr 17;14:34. doi: 10.1186/1475-2867-14-34. eCollection 2014. Cancer Cell Int. 2014. PMID: 24739220 Free PMC article. Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources